PPARG antibody (N-Term)

Catalog No. ABIN966886

Product Details anti-PPARG Antibody

Target: PPARG (Peroxisome Proliferator-Activated Receptor gamma (PPARG))

Binding Specificity: N-Term

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PPARG antibody is un-conjugated

Application: Western Blotting (WB)

Cross-Reactivity (Details): No cross reactivity with other proteins.

Characteristics: Rabbit IgG polyclonal antibody for Peroxisome proliferator-activated receptor gamma ( PPARG) detection. Tested with WB in Human.

Immunogen: A synthetic peptide corresponding to a sequence at the N-terminal of human PPAR-G, different from the rat and mouse sequences by two amino acids.< br/>Immunogen was affinity purified.

Isotype: IgG

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 µg/mL.

Buffer: Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Thimerosal, 0.05 mg Sodium azide.

Preservative: Sodium azide, Thimerosal (Merthiolate)

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: At -20 °C for one year. After reconstitution, at 4 °C for one month. It can also be aliquotted and stored frozen at -20 °C for a longer time.

References for anti-PPARG antibody (ABIN966886)

Ameshima, Golpon, Cool, Chan, Vandivier, Gardai, Wick, Nemenoff, Geraci, Voelkel: "Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth." in: Circulation research, Vol. 92, Issue 10, pp. 1162-9, (2003) (PubMed).

Berger, Moller: "The mechanisms of action of PPARs." in: Annual review of medicine, Vol. 53, pp. 409-35, (2002) (PubMed).

Deeb, Fajas, Nemoto, Pihlajamäki, Mykkänen, Kuusisto, Laakso, Fujimoto, Auwerx: "A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity." in: Nature genetics, Vol. 20, Issue 3, pp. 284-7, (1998) (PubMed).

Target Details for PPARG

Target: PPARG (Peroxisome Proliferator-Activated Receptor gamma (PPARG))

Abstract: PPARG Products

Synonyms: PPAR gamma antibody, PPARg2 antibody, PPARG antibody, Nr1c3 antibody, PPAR-gamma antibody, PPAR-gamma2 antibody, PPARgamma antibody, PPARgamma2 antibody, NR1C3 antibody, CIMT1 antibody, GLM1 antibody, PPARG1 antibody, PPARG2 antibody, xPPAR-gamma antibody, PPAR-GAMMA antibody, PPARGAMMA antibody, peroxisome proliferator-activated receptor gamma antibody, peroxisome proliferator activated receptor gamma antibody, peroxisome proliferator activated receptor gamma L homeolog antibody, PPARG antibody, Pparg antibody, pparg.L antibody

Background: The peroxisome proliferator-activated receptors (PPARs) are a group of three nuclear receptor isoforms, PPAR gamma, PPAR alpha, and PPAR delta, encoded by different genes. PPARs are ligand-regulated transcription factors that control gene expression by binding to specific response elements (PPREs) within promoters. PPAR gamma is a transcription factor that has a pivotal role in adipocyte differentiation and expression of adipocyte-specific genes. The PPAR gamma1 and gamma2 isoforms result from alternative splicing and have ligand-dependent and -independent activation domains. PPAR gamma is a member of a family of nuclear receptors/ligand-dependent transcription factors, which bind to hormone response elements on target gene promoters. Ameshima et al. (2003) found that PPAR gamma is abundantly expressed in normal lung tissues, especially in endothelial cells, but that its expression is reduced or absent in the angiogenic plexiform lesions of pulmonary hypertensive lungs and in the vascular lesions of a rat model of severe pulmonary hypertension. And they conclude that fluid shear stress decreases the expression of PPARgamma in endothelial cells and that loss of PPARgamma expression characterizes an abnormal, proliferating, apoptosis-resistant endothelial cell phenotype.

Pathways: MAPK Signaling, Nuclear Receptor Transcription Pathway, Steroid Hormone Mediated Signaling Pathway, Negative Regulation of Hormone Secretion, Carbohydrate Homeostasis, Regulation of Lipid Metabolism by PPARalpha, Positive Regulation of Endopeptidase Activity, Brown Fat Cell Differentiation, Positive Regulation of fat Cell Differentiation